Oriahnn FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved May 29, 2020)
Brand name: Oriahnn
Generic name: elagolix/estradiol/norethindrone acetate and elagolix
Dosage form: Capsules
Company: AbbVie Inc.
Treatment for: Uterine Leiomyomata
Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist, estrogen and progestin co-formulation indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
Development timeline for Oriahnn
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
